NL-OMON45549招募中不适用
Immune monitoring in pancreatic cancer - Immune monitoring in pancreatic cancer
Stichting Leveronderzoek0 个研究点目标入组 400 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age >= 18 years
- •Diagnosed with resectable or borderline resectable pancreatic cancer, locally
- •advanced pancreatic cancer or metastasized pancreatic cancer
- •Planned treatment with either currently available standard of care treatments
- •for pancreatic cancer (e.g. surgery, gemcitabine, neoadjuvant
- •chemoradiotherapy, FOLFIRINOX and/or (stereotactic) radiotherapy) or new
- •treatment options such as, but not limited to, Ampligen® (immunotherapy) or DC
- •Signed informed consent
排除标准
- •Unable to draw blood for study purposes
- •Serious concomitant systemic disorders that would compromise the safety of
- •the patient or his/her ability to complete the study, at the discretion of the
- •investigator.
研究者
相似试验
招募中
不适用
Analyses of immune status in cancer patientsMalignant tumorJPRN-UMIN000040469Chiba Cancer Center150
已完成
不适用
Assessment of tumor response to immune checkpoint inhibitors using chest magnetic resonance imagingadvanced lung cancerJPRN-UMIN000023462Hamamatsu University School of Medicine20
招募中
不适用
The search for biomarkers reflecting tumor immune microenvironment for renal cell carcinomaRenal cell carcinomaJPRN-UMIN000029326Tokyo Medical and Dental University, Medical Hospital600
尚未招募
不适用
Immune profiling of tumor and blood of patients with nasopharyngeal cancerasopharynx cancernasopharyngeal carcinomaNL-OMON51134Select40
已完成
不适用
Cellular & Serological Immune Response Monitoring in SARS-CoV2-infected individuals, without need of hospitalizatioCorona virusCOVID-191004743810024970NL-OMON50071eids Universitair Medisch Centrum10